American Journal of Kidney Diseases
Volume 55, Issue 6 , Pages 1050-1059 , June 2010

ADMA, C-Reactive Protein, and Albuminuria in Untreated Essential Hypertension: A Cross-sectional Study

  • Costas Tsioufis, MD, PhD

      Affiliations

    • First Cardiology Clinic, University of Athens, Hippokration Hospital, Athens, Greece
    • Corresponding Author InformationAddress correspondence to Costas Tsioufis, MD, PhD, FESC, 43, Agias Marinas Str, 15127 Melissia, Athens, Greece
    • ,
  • Kyriakos Dimitriadis, MD

      Affiliations

    • First Cardiology Clinic, University of Athens, Hippokration Hospital, Athens, Greece
    • ,
  • Eirini Andrikou, MD

      Affiliations

    • First Cardiology Clinic, University of Athens, Hippokration Hospital, Athens, Greece
    • ,
  • Costas Thomopoulos, MD

      Affiliations

    • First Cardiology Clinic, University of Athens, Hippokration Hospital, Athens, Greece
    • ,
  • Dimitris Tsiachris, MD

      Affiliations

    • First Cardiology Clinic, University of Athens, Hippokration Hospital, Athens, Greece
    • ,
  • Elli Stefanadi, MD

      Affiliations

    • First Cardiology Clinic, University of Athens, Hippokration Hospital, Athens, Greece
    • ,
  • Costas Mihas, MD

      Affiliations

    • First Cardiology Clinic, University of Athens, Hippokration Hospital, Athens, Greece
    • ,
  • Antigoni Miliou, PhD

      Affiliations

    • First Cardiology Clinic, University of Athens, Hippokration Hospital, Athens, Greece
    • ,
  • Vassilios Papademetriou, MD, PhD

      Affiliations

    • Hypertension and Cardiovascular Research Clinic, Veterans Affairs Medical Center, Washington, DC
    • ,
  • Christodoulos Stefanadis, MD, PhD

      Affiliations

    • First Cardiology Clinic, University of Athens, Hippokration Hospital, Athens, Greece

Received 29 June 2009 ,Accepted 16 November 2009.

References 

  1. Pedrinelli R, Dell' Omo G, Di Bello V, Pontremolli R, Mariani M. Microalbuminuria, an integrated marker of cardiovascular risk in essential hypertension. J Hum Hypertens. 2002;16:79–89
  2. Geirstein H, Mann J, Qilong Yi, et al. HOPE Study Investigators Albuminuria and risk of cardiovascular events and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421–426
  3. Tsioufis C, Dimitriadis K, Antoniadis D, Stefanadis C, Kallikazaros I. Inter-relationships of microalbuminuria with the other surrogates of the atherosclerotic cardiovascular disease in hypertensive subjects. Am J Hypertens. 2004;17:470–476
  4. Tsioufis C, Dimitriadis K, Chatzis D, et al. Relation of microalbuminuria to adiponectin and augmented C-reactive protein levels in men with essential hypertension. Am J Cardiol. 2005;96:946–951
  5. Pedrinelli R, Dell'Omo G, Di Bello V, et al. Low-grade inflammation and microalbuminuria in hypertension. Arterioscler Thromb Vasc Biol. 2004;24:2414–2419
  6. Tsioufis C, Dimitriadis K, Taxiarchou E, et al. Diverse associations of microalbuminuria with C-reactive protein, interleukin-18 and soluble CD 40 ligand in male essential hypertensive subjects. Am J Hypertens. 2006;19:462–466
  7. Engstrom G, Janson L, Berglund G, et al. Inflammation-sensitive plasma proteins and incidence of myocardial infarction in men with low cardiovascular risk. Arterioscler Thromb Vasc Biol. 2003;23:2247–2251
  8. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-Reactive protein and the risk of developing hypertension. JAMA. 2003;290(22):2945–2951
  9. Schillaci G, Pirro M, Gemelli F, et al. Increased C-reactive protein concentrations in never-treated hypertension: the role of systolic and pulse pressures. J Hypertens. 2003;21:1841–1846
  10. Chae C, Lee R, Rifai N, Ridker P. Blood pressure and inflammation in apparently healthy men. Hypertension. 2001;38:399–403
  11. Dzau VJ. Angiotensin and pathophysiology of vascular disease: a unifying hypothesis. Hypertension. 2001;37:1047–1052
  12. Kuwahara F, Kai H, Niiyama H, et al. Roles of intercellular adhesion molecule-1 in hypertensive cardiac remodeling. Hypertension. 2003;41:819–823
  13. Stuveling EM, Bakker SJ, Hillege HL, et al. PREVEND Study Group C-Reactive protein modifies the relationship between blood pressure and microalbuminuria. Hypertension. 2004;43:791–796
  14. Cooke JP. Asymmetrical dimethylargine (The uber marker?). Circulation. 2004;109:1813–1819
  15. Zoccali C. Asymmetrical dimethylargine (ADMA): a cardiovascular and renal risk factor on the move. J Hypertens. 2006;24:611–619
  16. Boger RH, Zoccali C. ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease. Atheroscler Suppl. 2003;4:23–28
  17. Kielstein JT, Impraim B, Simmel S, et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation. 2004;109:172–179
  18. Kielstein JT, Bode-Boger SM, Frolich JC, Ritz E, Haller H, Fliser D. Asymmetric dimethylarginine, blood pressure and renal perfusion in elderly subjects. Circulation. 2003;107:1891–1895
  19. Zoccali C, Bode-Boger S, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 2001;358:2113–2117
  20. Palloshi A, Fragasso G, Piatti P, et al. Effect of oral l-arginine on blood pressure and symptoms and endothelial function in patients with systemic hypertension, positive exercise test and normal coronary arteries. Am J Cardiol. 2004;93:930–935
  21. Takiushi S, Fujii H, Kamide K, et al. Plasma asymmetric dimethylarginine and coronary and peripheral endothelial dysfunction in hypertensive patients. Am J Hypertens. 2004;17:802–808
  22. Perticone F, Sciacqua A, Maio R, et al. Asymmetric dimethylarginine, l-arginine and endothelial dysfunction in essential hypertension. J Am Coll Cardiol. 2005;46:518–523
  23. Furuki K, Hisashi A, Matsuoka H, et al. Plasma levels of asymmetric dimethylarginine (ADMA) are related to intima-media thickness of the carotid artery (An epidemiological study). Atherosclerosis. 2007;191:206–210
  24. Zoccali C, Mallamaci F, Maas R, et al. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int. 2002;62:339–345
  25. Krzyzanowska K, Mittermayer F, Shnawa N, et al. Asymmetrical dimethylarginine is related to renal function, chronic inflammation and macroangiopathy in patients with type 2 diabetes and albuminuria. Diabet Med. 2007;24:81–86
  26. Caglar K, Yilmaz MI, Sonmez A, et al. ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. Kidney Int. 2006;70:781–787
  27. Tsioufis C, Tsiachris D, Dimitriadis K, et al. Evidence for no global effect of metabolic syndrome per se on early hypertensive sequelae. J Hypertens. 2008;26:773–779
  28. Mancia G, de Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105–1187
  29. Tsioufis C, Stefanadis C, Antoniadis D, et al. Absence of any significant effects of circadian blood pressure variations on carotid artery elastic properties in essential hypertensive subjects. J Hum Hypertens. 2000;14:813–818
  30. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: evaluation, classification and stratification. Am J Kidney Dis. 2002;39(2 suppl 1):S1–S266
  31. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricular dimensions by two-dimensional echocardiography (American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of the Two-Dimensional Echocardiograms). J Am Soc Echocardiogr. 1989;2:358–367
  32. Valtonen P, Karppi J, Nyyssonen K, Valkonen VP, Halonen T, Punnonen K. Comparison of HPLC method and commercial ELISA assay for asymmetric dimethylarginine (ADMA) determination in human serum. J Chromatogr B Analyt Technol Biomd Life Sci. 2005;828:97–102
  33. Surdai A, Nowicki M, Sandmann J, et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetrical dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol. 1999;33:652–658
  34. Konukoglu D, Firtine S, Serin O. The relationship between plasma asymmetrical dimethyl-l-arginine and inflammation and adhesion molecule levels in subjects with normal, impaired and diabetic glucose tolerance. Metabolism. 2008;57(1):110–115
  35. Verdecchia P, Schillaci G, Borgioni C, et al. Ambulatory pulse pressure: a potent predictor of total cardiovascular risk in hypertension. Hypertension. 1998;32:983–988
  36. Kielstein JT, Donnerstag F, Gasper S, et al. ADMA increases arterial stiffness and decreases blood flow in humans. Stroke. 2006;37:2024–2029
  37. Tsioufis C, Dimitriadis K, Kallikazaros I, Stefanadis C. The emerging role of subclinical inflammation in hypertension-associated early renal dysfunction: focus on microalbuminuria. Hellenic J Cardiol. 2006;47(6):361–365
  38. Krzyzanowska K, Mittermayer F, Wolzt M, Schernthaner G. Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes. Diabetes Care. 2007;30:1834–1839
  39. Di Napoli M, Papa F. Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first ever ischemic stroke. Stroke. 2003;34:2922–2929
  40. Delles C, Schneider MP, John S, Gekle M, Schmieder RE. Angiotensin converting enzyme inhibition and angiotensin II AT-1 receptor blockade reduce the levels of asymmetrical N(G), N(G)-dimethylarginine in human essential hypertension. Am J Hypertens. 2002;15:590–593

 Originally published online as doi:10.1053/j.ajkd.2009.11.024 on March 2, 2010.

PII: S0272-6386(09)01666-7

doi: 10.1053/j.ajkd.2009.11.024

American Journal of Kidney Diseases
Volume 55, Issue 6 , Pages 1050-1059 , June 2010

Article Tools

* Image Usage & Resolution